YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma Journal Article


Authors: Hottinger, A. F.; Iwamoto, F. M.; Karimi, S.; Riedel, E.; Dantis, J.; Park, J.; Panageas, K. S.; Lassman, A. B.; Abrey, L. E.; Fleisher, M.; Holland, E. C.; Deangelis, L. M.; Hormigo, A.
Article Title: YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
Abstract: Objective: To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL). Methods: In this prospective longitudinal study, serum samples from consecutive patients with histologically confirmed PCNSL were collected concurrently with magnetic resonance imaging (MRI) scans at multiple time points and were analyzed for levels of YKL-40 and MMP-9 by enzyme-linked immunosorbent assay. Marker levels were correlated to disease status and survival. Results: Forty-five patients with PCNSL were accrued. Median follow-up for survivors was 25 months, and 21 (47%) died during the study. A total of 230 serum samples were collected, and 93% had corresponding MRI scans. PCNSL patients without evidence of radiographic disease (29 patients, 131 samples) had significantly lower levels of serum YKL-40 and MMP-9 than patients with active tumor (n = 34 patients, 84 samples; p = 0.03 and 0.01, respectively). There was a significant inverse correlation between survival and doubling of the YKL-40 level (hazard ratio, 1.7; p = 0.01). Interpretation: In patients with PCNSL, serum levels of YKL-40 and MMP-9 are associated with radiographic disease status. Longitudinal increase in serum levels of YKL-40, but not MMP-9, predicts survival in patients with PCNSL. ANN NEUROL 2011 © 2011 American Neurological Association.
Keywords: adult; cancer survival; clinical article; aged; unclassified drug; disease course; primary central nervous system lymphoma; nuclear magnetic resonance imaging; follow up; tumor volume; gelatinase b; tumor marker; enzyme linked immunosorbent assay; cancer survivor; correlation analysis; blood level; ykl 40 protein
Journal Title: Annals of Neurology
Volume: 70
Issue: 1
ISSN: 0364-5134
Publisher: Wiley Blackwell  
Date Published: 2011-07-01
Start Page: 163
End Page: 169
Language: English
DOI: 10.1002/ana.22360
PROVIDER: scopus
PUBMED: 21391238
PMCID: PMC7295085
DOI/URL:
Notes: --- - "Export Date: 3 October 2011" - "CODEN: ANNED" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph Park
    2 Park
  2. Fabio M Iwamoto
    36 Iwamoto
  3. Andrew Lassman
    111 Lassman
  4. Sasan Karimi
    114 Karimi
  5. Eric Holland
    225 Holland
  6. Adilia Hormigo
    49 Hormigo
  7. Lauren E Abrey
    278 Abrey
  8. Katherine S Panageas
    512 Panageas
  9. Martin Fleisher
    312 Fleisher
  10. Jocelyn Dantis
    4 Dantis